Cargando…
Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies
Bedaquiline is a newly developed anti-tuberculosis drug, conditionally approved by the United States Food and Drug Administration (USFDA) for treating drug-resistant tuberculosis in adults. Oral delivery of bedaquiline causes severe side effects such as increased hepatic aminotransferase levels and...
Autores principales: | Momin, Mohammad A. M., Rangnekar, Bhamini, Sinha, Shubhra, Cheung, Chen-Yi, Cook, Gregory M., Das, Shyamal C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836091/ https://www.ncbi.nlm.nih.gov/pubmed/31581469 http://dx.doi.org/10.3390/pharmaceutics11100502 |
Ejemplares similares
-
Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder
por: Saha, Tushar, et al.
Publicado: (2022) -
Inhalable Combination Powder Formulations for Treating Latent and Multidrug-Resistant Tuberculosis: Formulation and In Vitro Characterization
por: Eedara, Basanth Babu, et al.
Publicado: (2023) -
Roflumilast Powders for Chronic Obstructive Pulmonary Disease: Formulation Design and the Influence of Device, Inhalation Flow Rate, and Storage Relative Humidity on Aerosolization
por: Momin, Mohammad A. M., et al.
Publicado: (2021) -
Amorphicity and Aerosolization of Soluplus-Based Inhalable Spray Dried Powders
por: Adhikari, Bishal Raj, et al.
Publicado: (2022) -
Spray-Dried Inhalable Microparticles Combining Remdesivir and Ebselen against SARS-CoV-2 Infection
por: Saha, Tushar, et al.
Publicado: (2023)